allogeneic iPS cell-derived retinal pigmented epithelium (RPE) cell suspension for RPE impaired disease - aiPSC-RPE CS transplantation forRID

Kurimoto Yasuo0 个研究点目标入组 50 人开始时间: 2021年1月28日最近更新: 2023年10月17日

试验速览

暂无简介。

•1) clinically diagnosed as RPE impaired disease on the diagnostic criteria
•2) male or female at 20 years of age or older
•3) Window defect is observed by FAG.
•4) collected visual acuity is less than 0.3 or less, or visual field measured with Goldman dynamic quantitative visual field (target: V-4) is within 20 degrees, or Estherman static quantitative visual field is 70 points or less.
•5) Capable of understanding the documents of the research context and of informed consent and is able to provide a written informed consent

•1) Ocular infection
•2) Glaucoma with poorly controlled intraocular pressure
•3) The affected eye was received intraocular surgeries other than cataract surgery within 3 months
•4) Any of bilirubin level, albumin level, and prothrombin time is outside the normal range as a criterion for liver function.
•5) Either creatinine level or eGFR (estimated glomerular filtration rate) is outside the normal range as a standard for renal function.
•6) B hepatitis virus, C hepatitis virus, human immunodeficiency virus, adult T-cell leukemia virus, cases of syphilis-positive
•7) Unable to quit anti-coagulants or antiplatelet medication
•8) Malignant carcinoma or its history in the past 3 years, however, this does not exclude patients with a history of carcinoma in situ.
•9) Family history of hereditary tumors
•10) Patients with contraindications for contrast agents, such as fluorescein or indocyanine green, antibacterial agents, steroids, immunosuppressants or anesthetics used in this clinical study
•11) May be pregnant during lactation or lactation. The patient or partner is planning a pregnancy.
•12) Participating in clinical studies involving other clinical trials or interventions within 1 month before obtaining consent or at the present time.
•13) Judged inadequate by the principal investigator and coresearchers
•14) When the case review meeting determines that it is unsuitable.

发起方

Kurimoto Yasuo